No Data
No Data
Earnings Preview: SAGE to Report Financial Results Post-market on October 29
TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $10
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $17
Scotiabank Reaffirms Their Buy Rating on SAGE Therapeutics (SAGE)
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
SAGE Therapeutics' Strategic Reorganization and Cautious Hold Rating Amid Development Setbacks